IDEAYA Biosciences, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
IDYA Nasdaq 2836 www.ideayabio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for IDEAYA Biosciences, Inc.

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - May 29th, 2026 4:00 am
IDEAYA Biosciences Spotlights Darovasertib Win, FDA Review Path at Oncology Summit - May 26th, 2026 5:03 pm
IDEAYA Biosciences Announces Participation at the 2026 Jefferies Global Healthcare Conference - May 26th, 2026 4:00 am
IDEAYA Biosciences Eyes Busy 2026 as Darovasertib Advances Toward FDA Filing - May 25th, 2026 5:07 am
IDEAYA Biosciences Says Melanoma Drug on Track for NDA After Strong Trial Data - May 17th, 2026 10:05 pm
Assessing IDEAYA Biosciences (IDYA) Valuation After Positive Darovasertib Phase 2/3 Results And FDA Real-Time Review - May 7th, 2026 1:17 pm
IDEAYA Biosciences, Inc. (IDYA) Reports Q1 Loss, Misses Revenue Estimates - May 5th, 2026 5:10 am
IDEAYA Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update - May 5th, 2026 4:00 am
Is IDEAYA Biosciences, Inc. (IDYA) A Good Stock To Buy Now? - May 3rd, 2026 12:41 pm
IDEAYA Biosciences to Initiate New Drug Application Submission from the Darovasertib OptimUM-02 Trial under the Oncology Center of Excellence Real-time Oncology Review (RTOR) Program - Apr 30th, 2026 4:00 am
IDEAYA Biosciences, Inc. (IDYA) PT Increased as Wedbush Highlights Positive OptimUM-02 Trial Readout - Apr 24th, 2026 7:41 am
IDEAYA Biosciences Announces Late-Breaking Abstract Oral Presentation at ASCO 2026 to Provide Complete Data from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in 1L HLA*A2-Negative Metastatic Uveal Melanoma - Apr 21st, 2026 8:15 am
Novo teams with OpenAI; Ideaya gets muted response to eye drug data - Apr 14th, 2026 2:55 am
IDEAYA Biosciences Unveils OptimUM-02 Data: Darovasertib/Crizotinib Doubles PFS in Uveal Melanoma - Apr 13th, 2026 11:02 pm
Ideaya Biosciences Surges On Promising Results For Hard-To-Treat Melanoma - Apr 13th, 2026 2:12 pm
Shares of This Cancer Therapy Maker Are Up 14%. Here’s Why. - Apr 13th, 2026 10:03 am
IDEAYA Biosciences and Servier Announce Positive Topline Results from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA-A*02:01-Negative Metastatic Uveal Melanoma - Apr 13th, 2026 4:00 am
IDEAYA Biosciences to Announce Topline Results from Phase 2/3 OptimUM-02 Trial in Metastatic Uveal Melanoma on Monday, April 13, 2026 - Apr 10th, 2026 2:05 pm
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE574, a Potential First-In Class Dual Inhibitor of KAT6/7 to Target Multiple Solid Tumor Indications, including Breast, Prostate, CRC, and Lung Cancer - Apr 6th, 2026 4:00 am
Why IDEAYA Biosciences (IDYA) Is Up 7.5% After Early Data From First-in-Class Cancer Combo - Apr 4th, 2026 3:11 am